VCYT
VERACYTE, INC.
Services-Medical Laboratories- 売上
- $517m
- 時価総額
- $4.4bn
株価 $55.65 · 100株 5,565円
がん診断と治療方針決定を支援する分子診断テストを医療機関に提供し収益を得る
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $361m | $446m | $517m |
| 成長率 | — | 23.5% | 16.0% |
| 総利益 | $230m | $298m | $363m |
| 総利益率 | 63.6% | 66.9% | 70.1% |
| 販管費 | $101m | $95m | $100m |
| 販管費率 | 28.1% | 21.4% | 19.4% |
| 営利 | ▲$86m | $16m | $58m |
| 営利率 | ▲23.8% | 3.6% | 11.2% |
| 純利益 | ▲$74m | $24m | $66m |
| PBR | 4.2 | 3.8 | 3.4 |
| PSR | 12.2 | 9.9 | 8.5 |
| PGPR | 19.2 | 14.8 | 12.2 |
| PER | — | 183 | 67 |
| ﾈｯﾄｷｬｯｼｭ | $216m | $239m | $362m |
| EV/EBITDA | — | 105.5 | 51.2 |
| Rule of 40 | — | 27% | 27% |
| セールス効率 | — | — | 1,358% |
※Rule of 40は売上成長率＋営業利益率、セールス効率は売上総利益増加÷販管費増加（販管費増のときのみ）